Table 1 Demographic and disease characteristics of the patients at baseline
Clinical characteristics | All patients | P value | Patients in group A | P value | ||
|---|---|---|---|---|---|---|
Group A (n = 30) | Group B (n = 32) | Single γδ T (n = 16) | Multiple γδ T (n = 14) | |||
Median age (years) | 63 (21–79) | 61 (23–80) | 0.759 | 62 (21–80) | 64 (23–78) | 0.998 |
Male sex | 17 (56.7%) | 19 (59.4%) | 0.829 | 9 (56.2%) | 8 (57.1%) | 0.961 |
Location | 0.885 | 0.881 | ||||
Head | 19 (63.3%) | 21 (65.6%) | 10 (62.5%) | 9 (64.3%) | ||
Body | 8 (26.7%) | 7 (21.9%) | 4 (25.0%) | 4 (28.6%) | ||
Uncinate process | 3 (10.0%) | 4 (12.5%) | 2 (12.5%) | 1 (7.1%) | ||
Median tumor diameter (cm) | 4 | 3.9 | 0.051 | 4.1 | 3.9 | 0.236 |
Median tumor volume (cm3) | 38.2 | 37.5 | 0.991 | 37.9 | 38.3 | 0.815 |
Previous surgical therapy | 0.863 | 0.685 | ||||
None | 19 (63.3%) | 21 (65.6%) | 10 (62.5%) | 9 (64.3%) | ||
Explorative laparotomy | 8 (26.7%) | 9 (28.1%) | 5 (31.3%) | 3 (21.4%) | ||
Others | 3 (10.0%) | 2 (6.3%) | 1 (6.3%) | 2 (14.3%) | ||
Chemotherapy before IRE | 0.944 | 0.993 | ||||
None | 6 (20.0%) | 7 (21.9%) | 3 (18.8%) | 3 (21.4%) | ||
Gemcitabine with or without nab-paclitaxel | 4 (13.3%) | 3 (9.4%) | 2 (12.5%) | 2 (14.3%) | ||
FOLFIRINOX | 18 (60.0%) | 19 (59.4%) | 10 (62.5%) | 8 (57.1%) | ||
Others | 2 (6.7%) | 3 (9.4%) | 1 (6.3%) | 1 (7.1%) | ||
